

# **Molecular Diagnostics**

## **Part II: Regulations, Markets & Companies**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**December 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His books include "Role of Nanobiotechnology in Molecular Diagnostics" (2006), "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011; 2<sup>nd</sup> ed Springer 2012, 3<sup>rd</sup> ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese edition 2012; 2<sup>nd</sup> ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese ed Chemical Industry Press 2016, 2<sup>nd</sup> ed Springer 2017), "Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011)", "Applications of Biotechnology in Neurology (Springer, 2013)", and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited "Applied Neurogenomics" (Springer 2015).

## **A B O U T   T H I S   R E P O R T**

Prof. Jain wrote the first commercial report on DNA Diagnostics covering scientific and commercial aspects in March 1995, which was published by PJB Publication, London. This was updated in 1997 as Molecular Diagnostics I and the next edition, Molecular Diagnostics II, was published in 1999 – both by Decision Resources Inc, USA. All the three versions of the reports were well accepted and sold widely. The current version was originally published by Jain PharmaBiotech in 2001 and is constantly updated since then. Not only was this the first such report on molecular diagnostics, it is the longest continuously published report (20 years). It is also the most comprehensive and detailed report on this topic containing profiles of the largest number of companies involved in molecular diagnostics.

**December 2017 (continuously published since 1995)  
Copyright ©2017 by**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax:       +4161-6924461  
Email:            info@pharmabiotech.ch  
Web site:         http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>12. Ethics, Patents and Regulatory issues.....</b>	<b>6</b>
<b>Introduction .....</b>	<b>6</b>
<b>Ethical concerns about genetic diagnosis.....</b>	<b>6</b>
Ethical guidelines for molecular diagnostics .....	7
Ethical aspects of use of WGS for newborn and prenatal screening .....	8
Ethical aspects of direct-to-consumer genetic services .....	8
US public attitudes about genetic testing .....	9
Opinion of European geneticists about DTC genetic testing .....	9
Genetic testing for susceptibility to adult-onset cancer .....	10
Ethics of preimplantation genetic diagnosis .....	10
<i>Preimplantation genetic diagnosis to screen for hereditary diseases .....</i>	<i>10</i>
<i>PGD to test for susceptibility to cancer.....</i>	<i>11</i>
<i>PGD and stem cells .....</i>	<i>11</i>
Genetic research on stored tissues .....	12
Informed consent in clinical trials of in vitro devices .....	12
Concluding remarks about ethical issues .....	12
Insurance underwriting and gene tests .....	13
<i>Should genetic information be available to health insurers?.....</i>	<i>13</i>
<i>A need for the re-examination of current views.....</i>	<i>14</i>
<i>Genetic Information Nondiscrimination Act of US .....</i>	<i>14</i>
<i>Impact of the US health care reform bill on genetic testing issues .....</i>	<i>14</i>
<b>Patents for molecular diagnostics.....</b>	<b>15</b>
PCR patents .....	15
Patenting DNA sequences .....	15
US policy on gene patenting relevant to molecular diagnostics.....	15
The impact of disease gene patents on molecular diagnostics .....	16
Licensing problems associated with genetic testing .....	16
BRCA1 and BRCA2 gene patents .....	17
<b>Role of the WHO in genetic testing standards.....</b>	<b>18</b>
<b>NIH's Genetic Testing Registry .....</b>	<b>18</b>
<b>Regulatory issues in the US .....</b>	<b>18</b>
Assay Migration Studies for In Vitro Diagnostic Devices .....	18
Assessment of diagnostic accuracy.....	19
<i>Sensitivity and specificity .....</i>	<i>19</i>
<i>Documentation of diagnostic accuracy .....</i>	<i>20</i>
Discovery of incidental findings on genetic screening .....	20
Evaluation of companion diagnostics/therapeutic for cancer .....	21
FDA regulation of multivariate index assays .....	21
FDA guidance for IVDs to detect pathogens.....	22
FDA guidelines for devices to detect and differentiate HPV .....	23
FDA's Microarray Quality Control.....	23
FDA and point-of-care diagnosis .....	24
Genetic testing of rare disorders .....	24
Guidelines for developing omics-based tests.....	25
<i>Shared responsibility on oversight of omics-based tests.....</i>	<i>26</i>
Guidelines for use of sequencing for molecular diagnosis .....	26
<i>FDA oversight of next generation sequencing .....</i>	<i>27</i>
Quality control of molecular diagnostic laboratory procedures.....	28
Quality assurance of RNA expression profiling.....	28
Quality control of point-of-care tests .....	29
Regulation of IVD by the FDA .....	29
FDA guidance on research use and investigational use only IVDs .....	31
Regulation of in vitro companion diagnostics by the FDA.....	31
Regulation of in vivo diagnostics by the FDA.....	32
Regulation of laboratory developed tests.....	32
<i>Home-brew tests .....</i>	<i>32</i>
<i>Laboratory-developed tests used by Medicare recipients .....</i>	<i>33</i>
<i>Oversight of LDTs by the FDA.....</i>	<i>34</i>
<i>Alternative to FDA LDT guidance .....</i>	<i>34</i>
Regulatory aspects of FISH .....	36
Regulation of genetic testing .....	36
<i>Role of the FDA in genetic testing .....</i>	<i>36</i>
Regulation of direct-to-consumer genetic testing .....	37
<i>Need for regulatory oversight of DTC.....</i>	<i>37</i>
Regulatory issues concerning blood and plasma products.....	39
United States Diagnostics Standards .....	39

<b>Regulation of in vitro diagnostics in the EU .....</b>	<b>40</b>
EU regulations for testing of blood products .....	41
Regulation of genetic testing in EU .....	41
Evaluation of diagnostic laboratory tests in the UK .....	42
Pre-implantation genetic diagnosis in the UK .....	43
<b>13. Markets for Molecular Diagnostics .....</b>	<b>44</b>
<b>Introduction .....</b>	<b>44</b>
<b>Methods for study of molecular diagnostic markets.....</b>	<b>44</b>
<b>The overall market for diagnostic technologies .....</b>	<b>45</b>
Markets for in vitro diagnostics .....	45
<b>Molecular diagnostic markets according to technologies .....</b>	<b>45</b>
Marketing strategies according to technologies .....	46
Nucleic acid isolation market .....	46
Market for PCR-based tests .....	46
<i>Markets for PCR instrumentation.....</i>	<i>47</i>
<i>Markets for real-time PCR and qRT-PCR.....</i>	<i>47</i>
<i>PCR market players.....</i>	<i>48</i>
DNA sequencing market.....	48
Cytogenetic market.....	48
<i>Market for FISH technologies.....</i>	<i>48</i>
Biochip/microarray market.....	49
Biosensor market.....	50
Nanobiotechnology for molecular diagnostics.....	50
Markets for gene expression technologies .....	50
Reagents and other disposable laboratory materials .....	50
Market for immunochemistry diagnostic.....	50
Markets for tissue diagnostics.....	51
<b>Molecular diagnostic markets according to therapeutic areas .....</b>	<b>51</b>
Genetic disorders .....	52
Prenatal testing .....	52
<i>Non-invasive prenatal testing .....</i>	<i>53</i>
Cancer.....	53
<i>Potential markets for cancer diagnosis according to type of cancer.....</i>	<i>54</i>
Infectious diseases.....	55
<i>Sexually transmitted diseases.....</i>	<i>56</i>
<i>Hospital-acquired infections.....</i>	<i>57</i>
<i>Testing for HIV drug resistance.....</i>	<i>58</i>
<i>Potential markets for avian influenza diagnostics .....</i>	<i>58</i>
Cardiovascular diseases .....	58
Neurological disorders .....	59
Food testing .....	59
Screening of blood for transfusion.....	59
Tissue typing for transplantation.....	59
<b>Molecular diagnostic markets relevant to pharmaceutical industry .....</b>	<b>59</b>
Molecular diagnosis and personalized medicine markets.....	60
Growth of markets relevant to personalized medicine .....	60
<i>Point-of-care market .....</i>	<i>60</i>
<b>Marketing opportunities according to geographic areas .....</b>	<b>61</b>
<b>Unmet needs in molecular diagnostics.....</b>	<b>61</b>
<b>Major market trends .....</b>	<b>62</b>
Markets according to home-brew and FDA-approved tests .....	62
Decentralization of molecular diagnostics .....	63
Point-of-care testing.....	63
Development of personalized medicine .....	64
<i>Cost of sequencing the human genome.....</i>	<i>64</i>
<i>Cost of genotyping.....</i>	<i>65</i>
<i>Marketing companion diagnostics for personalized medicine .....</i>	<i>65</i>
Development of low-cost tests.....	66
Simplification of test procedures .....	66
Increasing role of proteomics in clinical diagnostics .....	66
Forensic and legal applications .....	67
Veterinary molecular diagnostics.....	67
<b>Marketing strategies.....</b>	<b>67</b>
Role of alliances in commercialization of molecular diagnostics .....	68
<i>Acquisitions vs collaborations .....</i>	<i>68</i>
<i>Analysis of collaborations in molecular diagnostics .....</i>	<i>72</i>
<i>Licensing of the technologies.....</i>	<i>72</i>
Strategies related to laboratory facilities and technologies .....	73
Strategies relevant to the healthcare system.....	73
<i>Cost-Benefit studies .....</i>	<i>73</i>

<i>Genetic susceptibility testing</i> .....	73
<i>Preventive medicine strategies</i> .....	74
<i>Targeting treatable and common diseases</i> .....	74
Information/education .....	74
<i>Physician education</i> .....	74
<i>Patient education</i> .....	75
<i>European diagnostic information platform</i> .....	76
Regulatory strategies .....	76
Merger of in vitro and in vivo diagnostics .....	76
Integration of diagnostics with therapeutics .....	76
Diagnostic applications in clinical trials .....	77
<b>Prospects for development of new technologies</b> .....	<b>77</b>
Drivers for the development of molecular diagnostics .....	77
Factors slowing the development of molecular diagnostics .....	77
Cost of sequencing the human genome .....	78
Challenges and future prospects for diagnostic applications of sequencing .....	79
US organizations for advancing molecular diagnostic industry.....	79
<i>AdvaMedDx</i> .....	79
European projects for improving molecular diagnostics.....	80
<i>European Consortium for developing new DNA analysis tools</i> .....	80
<i>EU project for improvement of IVD tools procedures</i> .....	80
<i>Genetic knowledge parks in the UK</i> .....	81
Molecular diagnostic opportunities in defense against bioterrorism .....	81
Molecular diagnostics for food safety .....	81
POC diagnostics for the Asian countries .....	82
<b>14. Companies involved in molecular diagnostics</b> .....	<b>84</b>
<b>Introduction</b> .....	<b>84</b>
<b>Major players in molecular diagnostics</b> .....	<b>84</b>
<b>Profiles of selected companies</b> .....	<b>85</b>
<b>Collaborations</b> .....	<b>517</b>

## Tables

Table 13-1: Share of in vitro diagnostics in the global diagnostic market 2016-2026 .....	45
Table 13-2: Molecular diagnostics markets according to technologies from 2016-2026 .....	46
Table 13-3: PCR market 2016-2026 .....	47
Table 13-4: Molecular diagnostics markets according to applications 2016-2026.....	51
Table 13-5: Markets in 2016 for tests to screen healthy persons for genetic disorders.....	52
Table 13-6: Markets in 2016 for molecular diagnostic screening tests for cancer.....	53
Table 13-7: Molecular diagnostic markets for selected cancers 2016-2026 .....	54
Table 13-8: Markets value in 2016 for molecular diagnostic screening for infections.....	55
Table 13-9: Future markets for HAI diagnostics 2016-2026 .....	57
Table 13-10: Growth of markets relevant to personalized medicine 2016-2026 .....	60
Table 13-11: Molecular diagnostic markets according to geographical areas 2016-2026 .....	61
Table 13-12: Molecular diagnostic markets according to home-brew and approved tests .....	63
Table 13-13: Marketing strategies for molecular diagnostics .....	67
Table 13-14: Acquisitions of molecular diagnostic companies .....	68
Table 13-15: Advantages of the integration of diagnostics with therapeutics .....	76
Table 14-1: Top ten players in molecular diagnostics .....	84
Table 14-2: Collaborations of companies in molecular diagnostics .....	517

## Figures

Figure 13-1: Unmet needs in applications of molecular diagnostics .....	62
---	----